Heron Therapeutics (HRTX) Raw Materials (2016 - 2026)
Heron Therapeutics' (HRTX) quarterly Raw Materials came in at $60.6 million in Q1 2026, up 210.43% YoY from $19.5 million in Q1 2025, and up 2.21% on a QoQ basis from $59.2 million in Q4 2025.
Heron Therapeutics (HRTX) Raw Materials (2016 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 11 years of Raw Materials data on file, last reported at $60.6 million in Q1 2026.
- Quarterly Raw Materials rose 210.43% year-over-year to $60.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.6 million (up 210.43% YoY) and the FY2025 annual result came in at $59.2 million, up 200.26% from the prior year.
- Raw Materials climbed to $60.6 million in Q1 2026, from $59.2 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $60.6 million in Q1 2026 to a low of $15.1 million in Q4 2022.
- A 5-year average of $25.6 million and a median of $19.6 million in 2024 frame the typical range for Raw Materials.
- Annual changes were most pronounced in 2023 — Raw Materials slumped 36.02% — and 2026, when it soared 210.43%.
- Tracing HRTX's Raw Materials over 5 years: stood at $15.1 million in 2022, then advanced by 16.56% to $17.6 million in 2023, then increased by 11.85% to $19.7 million in 2024, then soared by 200.26% to $59.2 million in 2025, then advanced by 2.21% to $60.6 million in 2026.
- The last three Raw Materials figures came in at $60.6 million (Q1 2026), $59.2 million (Q4 2025), and $32.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - |
| 10 | Heron Therapeutics | 60.64 Mn | 17.98 Mn | 26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.09 Mn |
| Mar 31, 2026 | 60.56 Mn |
| Dec 31, 2025 | 59.25 Mn |
| Sep 30, 2025 | 32.79 Mn |
| Jun 30, 2025 | 35.82 Mn |
| Mar 31, 2025 | 19.51 Mn |
| Dec 31, 2024 | 19.73 Mn |
| Sep 30, 2024 | 20.82 Mn |
| Jun 30, 2024 | 19.59 Mn |
| Mar 31, 2024 | 18.08 Mn |
| Dec 31, 2023 | 17.64 Mn |
| Sep 30, 2023 | 15.61 Mn |
| Jun 30, 2023 | 18.41 Mn |
| Mar 31, 2023 | 16.41 Mn |
| Dec 31, 2022 | 15.14 Mn |
| Sep 30, 2022 | 18.59 Mn |
| Jun 30, 2022 | 21.83 Mn |
| Mar 31, 2022 | 25.65 Mn |
| Dec 31, 2021 | 21.19 Mn |
| Sep 30, 2021 | 20.98 Mn |